Liminal BioSciences Inc. LMNL

Healthcare Biotechnology

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.

NDAQ:LMNL - Post by User

Liminal BioSciences Inc. > What did they say about our expected partnership????

<< Previous

Bullboard Posts

Next >>

Comment by stockbuphoonon Mar 20, 2020 9:19pm

115 Views

Post# 30832572

RE:RE:RE:RE:What did they say about our expected partnership????

They have backed off the partnership in H1. There is no date associated with this statement and they are exploring alternatives and not focused on sealing a deal from the way they have written it. If they are on track for any partnership in H1, they have the worst marketing people ever.

"Exploring alternatives for the future commercialization of Ryplazim^®, if approved, including through a third-party marketing collaboration, and other ongoing preparation for the potential commercial launch of Ryplazim^®, if approved, in the United States"

realstocky wrote:
Jesus dude, read it!: "We are looking forward to our expected resubmission, in the first half of 2020, of a Biological License Application ("BLA") with the United States Food and Drug Administration ("FDA") for Ryplazim®
__________________________________________________________________________

partnership comes prior, to be ready on FDA decision so we are ready to launch.

Anticipated Key Milestones

1H-2020Expected commercial partnership for Ryplazim™

1H-2020Expected filing of amended BLA with FDA for Ryplazim™ (priority review expected)